{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:31:55Z","timestamp":1792225915896,"version":"4.4.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"52","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T00:00:00Z","timestamp":1476921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.vaccine.2016.10.039","type":"journal-article","created":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T22:01:04Z","timestamp":1478642464000},"page":"6672-6680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":121,"title":["Vaccine safety evaluation: Practical aspects in assessing benefits and risks"],"prefix":"10.1016","volume":"34","author":[{"given":"Alberta","family":"Di Pasquale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2875-3744","authenticated-orcid":false,"given":"Paolo","family":"Bonanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Gar\u00e7on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence R.","family":"Stanberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"El-Hodhod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Tavares Da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.10.039_b0005","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). EMA\/876333\/2011 Rev 3; 2011."},{"key":"10.1016\/j.vaccine.2016.10.039_b0010","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/risa.12114","article-title":"Understanding public perceptions of benefits and risks of childhood vaccinations in the United States","volume":"34","author":"Song","year":"2014","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2016.10.039_b0015","series-title":"Immunization safety review: measles-mumps-rubella vaccine and autism","author":"Institute of Medicine (US) Immunization Safety Review Committee","year":"2001"},{"key":"10.1016\/j.vaccine.2016.10.039_b0020","unstructured":"Update: vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep, vol. 45; 1996. p. 1\u201335."},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2016.10.039_b0025","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1542\/peds.2010-1722D","article-title":"Ensuring the optimal safety of licensed vaccines: a perspective of the vaccine research, development, and manufacturing companies","volume":"127","author":"Kanesa-thasan","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2016.10.039_b0030","unstructured":"Center for drug evaluation and research. Food and drug administration. Guidance for industry. E2E pharmacovigilance planning; 2005."},{"key":"10.1016\/j.vaccine.2016.10.039_b0035","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.vaccine.2014.10.047","article-title":"The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines","volume":"33","author":"Lopalco","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.039_b0040","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1586\/14760584.2014.959931","article-title":"Strategies for continuous evaluation of the benefit-risk profile of HPV-16\/18-AS04-adjuvanted vaccine","volume":"13","author":"Angelo","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2016.10.039_b0045","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1542\/peds.2009-2489","article-title":"On-time vaccine receipt in the first year does not adversely affect neuropsychological outcomes","volume":"125","author":"Smith","year":"2010","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2016.10.039_b0050","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jpeds.2013.02.001","article-title":"Increasing exposure to antibody-stimulating proteins and polysaccharides in vaccines is not associated with risk of autism","volume":"163","author":"DeStefano","year":"2013","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2016.10.039_b0055","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1586\/14760584.2014.866895","article-title":"Active surveillance for adverse events following immunization","volume":"13","author":"Crawford","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2016.10.039_b0060","first-page":"828","article-title":"Vaccinovigilance in Europe\u2013need for timeliness, standardization and resources","volume":"82","author":"Lankinen","year":"2004","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2016.10.039_b0065","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions : a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2016.10.039_b0070","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1586\/14760584.2014.891941","article-title":"Perspectives on the future of postmarket vaccine safety surveillance and evaluation","volume":"13","author":"Ball","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2016.10.039_b0075","unstructured":"Centers for Disease Control and Prevention. Vaccines and immunizations. Rotavirus Vaccine (RotaShield\u00ae) and Intussusception; 2014. <http:\/\/www.cdc.gov\/vaccines\/vpd-vac\/rotavirus\/vac-rotashield-historical.htm> [accessed March 10, 2016]."},{"key":"10.1016\/j.vaccine.2016.10.039_b0080","unstructured":"Centers for Disease Control and Prevention (CDC). Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep, vol. 48; 1999. p. 1007."},{"key":"10.1016\/j.vaccine.2016.10.039_b0085","unstructured":"Rotavirus vaccines. WHO position paper \u2013 January 2013. Wkly Epidemiol Rec, vol. 88; 2013. p. 49\u201364."},{"key":"10.1016\/j.vaccine.2016.10.039_b0090","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1053\/spid.2002.125864","article-title":"The science of evaluation of adverse events associated with vaccination","volume":"13","author":"Halsey","year":"2002","journal-title":"Semin Pediatr Infect Dis"},{"key":"10.1016\/j.vaccine.2016.10.039_b0095","unstructured":"World Health Organization. Causality assessment of an adverse events following immunization (AEFI). User manual for the revised WHO classification; 2013."},{"key":"10.1016\/j.vaccine.2016.10.039_b0100","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.1016\/j.vaccine.2012.04.005","article-title":"Algorithm to assess causality after individual adverse events following immunizations","volume":"30","author":"Halsey","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.039_b0105","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jpeds.2013.01.028","article-title":"Comprehensive assessment of serious adverse events following immunization by health care providers","volume":"162","author":"Williams","year":"2013","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2016.10.039_b0110","doi-asserted-by":"crossref","first-page":"6349","DOI":"10.1016\/j.vaccine.2008.09.002","article-title":"Applicability, reliability, sensitivity, and specificity of six Brighton Collaboration standardized case definitions for adverse events following immunization","volume":"26","author":"Kohl","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.039_b0115","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/pds.851","article-title":"The Brighton Collaboration: enhancing comparability of vaccine safety data","volume":"12","author":"Kohl","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2016.10.039_b0120","doi-asserted-by":"crossref","first-page":"E84","DOI":"10.1542\/peds.107.5.e84","article-title":"Measles-mumps-rubella vaccine and autistic spectrum disorder: report from the New Challenges in Childhood Immunizations Conference convened in Oak Brook, Illinois, June 12-13, 2000","volume":"107","author":"Halsey","year":"2001","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2016.10.039_b0125","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(97)11096-0","article-title":"Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children","volume":"351","author":"Wakefield","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.10.039_b0130","first-page":"739","article-title":"Safety of oral poliomyelitis vaccine: results of a WHO enquiry","volume":"66","author":"Esteves","year":"1988","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2016.10.039_b0135","unstructured":"Vaccine Safety Datalink (VSD). Monitoring, ensuring safety, vaccine safety. CDC. <http:\/\/www.cdc.gov\/vaccinesafety\/ensuringsafety\/monitoring\/vsd\/index.html> [accessed September 24, 2015]."},{"key":"10.1016\/j.vaccine.2016.10.039_b0140","unstructured":"Institute of medicine reports on vaccine safety IOM reports. Research. Vaccine safety <http:\/\/www.cdc.gov\/vaccinesafety\/research\/iomreports\/index.html> [accessed September 24, 2015]."},{"key":"10.1016\/j.vaccine.2016.10.039_b0145","unstructured":"Vaccine adverse event surveillance & communication. <http:\/\/vaesco.net\/vaesco.html> [accessed September 24, 2015]."},{"key":"10.1016\/j.vaccine.2016.10.039_b0150","unstructured":"World Health Organization. The global advisory committee on vaccine safety. <http:\/\/www.who.int\/vaccine_safety\/committee\/en\/> [accessed September 24, 2015]."},{"key":"10.1016\/j.vaccine.2016.10.039_b0155","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40264-014-0194-3","article-title":"A comparison of active adverse event surveillance systems worldwide","volume":"37","author":"Huang","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2016.10.039_b0160","first-page":"216","article-title":"Presenting the case for an immunization safety surveillance system","volume":"78","author":"Darwish","year":"2000","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2016.10.039_b0165","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). EMA\/838713\/2011 Rdv1; 2013. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/06\/WC500129137.pdf> [accessed June 14, 2015]."},{"key":"10.1016\/j.vaccine.2016.10.039_b0170","doi-asserted-by":"crossref","unstructured":"NVAC report and recommendations approved by the national vaccine advisory committee on September 12, 2013. NVAC Recommendation 3: enhancing global capacity for vaccine safety monitoring and post-marketing surveillance. Public health reports, vol. 129; 2014. p. 54\u20139.","DOI":"10.1177\/00333549141295S305"},{"key":"10.1016\/j.vaccine.2016.10.039_b0175","unstructured":"World Health Organization. Global manual on surveillance of adverse events following immunization; 2014."},{"key":"10.1016\/j.vaccine.2016.10.039_b0180","doi-asserted-by":"crossref","first-page":"20587","DOI":"10.2807\/1560-7917.ES2013.18.38.20587","article-title":"Pertussis immunisation and control in England and Wales, 1957 to 2012: a historical review","volume":"18","author":"Amirthalingam","year":"2013","journal-title":"Euro Surveill"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2016.10.039_b0185","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1086\/515063","article-title":"Experience with diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine in Japan","volume":"28","author":"Sato","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2016.10.039_b0190","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1586\/14760584.4.2.173","article-title":"Acellular pertussis vaccines in Japan: past, present and future","volume":"4","author":"Watanabe","year":"2005","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2016.10.039_b0195","unstructured":"Public Health England. Completed primary courses at two years of age: England and Wales, 1966\u20131977, England only 1978 onwards. <https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/356061\/The_Immunisation_Coverage_1966_2012_13.pdf> [accessed 01 February 2016]."},{"key":"10.1016\/j.vaccine.2016.10.039_b0200","first-page":"19","article-title":"Measles outbreak in Greater Manchester, England, October 2012 to September 2013: epidemiology and control","author":"Pegorie","year":"2014","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2016.10.039_b0205","unstructured":"Public Health England. The National Archives. Confirmed cases of Measles, Mumps and Rubella 1996\u20132013; 2014. <http:\/\/webarchive.nationalarchives.gov.uk\/20140505192926\/http:\/\/www.hpa.org.uk\/web\/HPAweb&HPAwebStandard\/HPAweb_C\/1195733833790> [accessed 01 February 2016]."},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2016.10.039_b0210","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1086\/315534","article-title":"Successful control of epidemic diphtheria in the states of the Former Union of Soviet Socialist Republics: lessons learned","volume":"181","author":"Dittmann","year":"2000","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2016.10.039_b0215","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.1086\/315567","article-title":"Contraindications to vaccination in the Russian Federation","volume":"181","author":"Tatochenko","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.10.039_b0220","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.ebiom.2015.07.003","article-title":"Investigating reports of complex regional pain syndrome: an analysis of HPV-16\/18-adjuvanted vaccine post-licensure data","volume":"2","author":"Huygen","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2016.10.039_b0225","unstructured":"European Medicines Agency - Human medicines - Human papillomavirus vaccines. HPV vaccines: EMA confirms evidence does not support that they cause CRPS or POTS; 2015. <http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/referrals\/Human_papillomavirus_vaccines\/human_referral_prac_000053.jsp&mid=WC0b01ac05805c516f> [accessed February 2, 2016]."},{"key":"10.1016\/j.vaccine.2016.10.039_b0250","doi-asserted-by":"crossref","first-page":"6655","DOI":"10.1016\/j.vaccine.2016.10.016","article-title":"Vaccine development: From concept to early clinical testing","volume":"34","author":"Cunningham","year":"2016","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16309744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16309744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T07:30:05Z","timestamp":1568532605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16309744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":46,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0264410X16309744"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.10.039","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccine safety evaluation: Practical aspects in assessing benefits and risks","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.10.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}